AMBIT BIOSCIENCES
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pha... rma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
AMBIT BIOSCIENCES
Industry:
Biopharma Biotechnology Health Care
Founded:
2000-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.ambitbio.com
Total Employee:
51+
Status:
Active
Contact:
(858) 334-2100
Total Funding:
215.73 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Google Font API WordPress Organization Schema Sitelinks Search Box Contact Form 7 Apache Tomcat Coyote
Similar Organizations
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
TargeGen
TargeGen, Inc., a vascular biology-focused biopharmaceutical company, discovers and develops small molecule kinase inhibitors that target.
Current Advisors List
Board_member
2010-10-01
Board_member
2013-01-01
Board_member
2001-01-01
Board_member
Board_member
Board_member
2011-01-01
Board_member
2009-01-01
Current Employees Featured
Alan Lewis President & CEO @ Ambit Biosciences
President & CEO
Founder
Stock Details
Investors List
Apposite Capital
Apposite Capital investment in Venture Round - Ambit Biosciences
Radius Ventures
Radius Ventures investment in Venture Round - Ambit Biosciences
Roche Venture Fund
Roche Venture Fund investment in Venture Round - Ambit Biosciences
GrowthWorks Capital
GrowthWorks Capital investment in Venture Round - Ambit Biosciences
Gimv
Gimv investment in Venture Round - Ambit Biosciences
Forward Ventures
Forward Ventures investment in Venture Round - Ambit Biosciences
Aisling Capital
Aisling Capital investment in Venture Round - Ambit Biosciences
MedImmune Ventures
MedImmune Ventures investment in Venture Round - Ambit Biosciences
OrbiMed
OrbiMed investment in Venture Round - Ambit Biosciences
Forward Ventures
Forward Ventures investment in Series D - Ambit Biosciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2008-09-19 | Afraxis | Ambit Biosciences investment in Series A - Afraxis | 1.5 M USD |
Official Site Inspections
http://www.ambitbio.com
- Host name: 172.67.160.111
- IP address: 172.67.160.111
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ambit Biosciences"
Ambit Biosciences Corporation | Ambit Biosciences Inc.
We are a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and …See details»
About Ambit | Ambit Biosciences Inc.
We are a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and …See details»
Ambit Biosciences - Crunchbase Company Profile
Contact Email sales@ambitbio.com Phone Number (858) 334-2100 Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the …See details»
Ambit Biosciences - Wikipedia
Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases. As of March 2014 , the company was based in San Diego, California, and consisted of a single facility. Ambit made an initial public offering in May 2013, and was listed on the NASDAQ exchange under the symbol "AMBI". Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange. See details»
Board of Directors | Ambit Biosciences Inc.
He is a member of the Board of Directors of the Biotechnology Industry Organization (BIO), serving on the Emerging Company Section, and the Capital Formation and Intellectual …See details»
Ambit Biosciences Corporation - Dun & Bradstreet
Company Description: Ambit Biosciences is using the scope of its expertise to find cures for hard-to-cure cancers. A biotechnology firm, Ambit discovers and develops drug …See details»
Ambit Biosciences
Nov 21, 2024 Founded in 2002, Ambit Biosciences is focused on discovering and developing small molecule drugs for treating cancer and autoimmune diseases. Ambit is a wholly owned …See details»
Ambit Biosciences Company Profile | Management and Employees …
Www.ambitbio.com Ambit Biosciences Profile and History Ambit Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of …See details»
Ambit - LinkedIn
Ambit | 581 followers on LinkedIn. Ambit Biosciences is combining the power of our KINOMEscan™ kinase profiling technology with an innovative licensing strategy and a history …See details»
Ambit Biosciences | Scientist.com
Ambitbio.com: Headquarters: San Diego, CA, US Company Type: Small Business (1-10M TTM Revenue) Description Sites Ambit offers kinase profiling and assay development services. ... If …See details»
Careers | Ambit Biosciences Inc.
Ambit maintains a strong company culture that promotes individual growth, integrity and teamwork. We offer competitive compensation and benefit programs (link to benefits page). If …See details»
Ambit Biosciences - VentureRadar
"Ambit Biosciences is a biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer.See details»
Daiichi Sankyo to Acquire Ambit Biosciences
Sep 29, 2014 “Daiichi Sankyo is the ideal organization to take quizartinib to the next stage of development, and ultimately, to achieve our goal of making it available as quickly as possible …See details»
Ambit Biosciences - PitchBook
Ambit Biosciences General Information Description. Developer of small molecule therapeutics for the treatment of cancer. The company focuses on the discovery and development of novel, …See details»
Investors | Ambit Biosciences Inc.
Ambit Biosciences has raised almost $165 million in private funding to date. Our investors are highly regarded in both the venture capital and biotechnology industries.See details»
Ambit Biosciences - Overview, News & Similar companies
Ambit Biosciences contact info: Phone number: (858) 334-2100 Website: www.ambitbio.com What does Ambit Biosciences do? Ambit Biosciences is a biopharmaceutical company …See details»
Working At Ambit: Company Overview and Culture - Zippia
Mar 14, 2024 www.ambitbio.com. Organization Type. Private. Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small …See details»
Scientific Advisors | Ambit Biosciences Inc.
Previously, as VP of Discovery Research at Parke-Davis he led a multi-national drug discovery organization of over 800 people, in cancer, infectious diseases, inflammation, cardiovascular …See details»
Ambit Biosciences Corporation | Insights
Oct 18, 2023 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Our Strategy | Ambit Biosciences Inc.
There are several key components to our strategy: Develop and seek regulatory approval for our lead drug candidate, quizartinib, in relapsed/refractory AML patients who express a genetic …See details»